Skip to main content
Signal8
Launch Terminal

Atea Pharmaceuticals, Inc. (AVIR)

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc.

NASDAQ:AVIRHealthcare
-4.64%$4.11
AH$4.11+0.00%vs close
Mkt Cap$329.64M
Float61.12M
O/S80.2M
Vol
$ Vol
RVOL
Inst Own74.2%
SI5.0%
Earnings
Dilution
Atea Pharmaceuticals, Inc. logoNASDAQ:AVIR$4.11-4.64%
Phase Distribution
33 lead-sponsored trials·2 active·27 completed
Phase 125
Phase 1/21
Phase 24
Phase 33
(3 more as collaborator)
Status Overview
Recruiting1
Active, not recruiting1
Completed27
Stopped4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

    Bemnifosbuvir (BEM), Placebo

    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19

    Enrollment
    2,285
    Start
    Nov 2022
    Primary Completion
    Apr 2024
    Completion
    May 2024
    NCT05629962
  • Phase 3
    Completed

    C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

    Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL)

    HEPATITIS C VIRUS CHRONIC INFECTION

    Enrollment
    940
    Start
    Apr 2025
    Primary Completion
    Jun 2026
    Completion
    Sep 2026
    NCT06868264
  • Phase 3
    Active, not recruiting

    C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

    Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir

    HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic +2

    Enrollment
    880
    Start
    Jun 2025
    Primary Completion
    Dec 2026est.
    Completion
    Mar 2027est.
    NCT07037277
  • Phase 2
    Completed

    Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

    AT-527, Daclatasvir

    Hepatitis C, Hepatitis C, Chronic +3

    Enrollment
    10
    Start
    Jun 2019
    Primary Completion
    Jan 2020
    Completion
    Mar 2020
    NCT04019717
  • Phase 2
    Terminated

    Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting

    AT-527, AT-527

    COVID-19

    Enrollment
    83
    Start
    May 2020
    Primary Completion
    Jan 2022
    Completion
    Feb 2022
    NCT04396106
  • Phase 2
    Terminated

    Study of AT-752 in Patients With Dengue Infection

    AT-752, Placebo

    Dengue Fever

    Enrollment
    21
    Start
    Apr 2022
    Primary Completion
    Jan 2023
    Completion
    Jan 2023
    NCT05466240
  • Phase 2
    Completed

    A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

    Bemnifosbuvir, Ruzasvir

    Chronic Hepatitis C Virus, Hepatitis C, Chronic +3

    Enrollment
    275
    Start
    May 2023
    Primary Completion
    Dec 2024
    Completion
    Jan 2025
    NCT05904470
  • Phase 1/2
    Withdrawn

    Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

    AT-777, Placebo

    Hepatitis C, Hepatitis C, Chronic +3

    Enrollment
    0
    Start
    Oct 2021est.
    Primary Completion
    Jun 2022est.
    Completion
    Sep 2022est.
    NCT04309734
  • Phase 1
    Completed

    Study of AT-527 in Healthy and HCV-Infected Subjects

    AT-527

    Chronic Hepatitis C, Hepatitis C +1

    Enrollment
    88
    Start
    Jul 2017
    Primary Completion
    Jun 2018
    Completion
    Jun 2018
    NCT03219957
  • Phase 1
    Completed

    Study of AT-527 in Healthy Subjects (R07496998)

    AT-527 Formulation 1, AT-527 Formulation 2

    Healthy Volunteer Study

    Enrollment
    81
    Start
    Nov 2020
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT04711187
  • Phase 1
    Completed

    Study of AT-752 in Healthy Subjects

    AT-752, Placebo

    Dengue

    Enrollment
    65
    Start
    Mar 2021
    Primary Completion
    Nov 2021
    Completion
    Nov 2021
    NCT04722627
  • Phase 1
    Completed

    Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

    Period 1: AT-527 550 mg, Period 2: carbamazepine

    Healthy Volunteer Study

    Enrollment
    20
    Start
    Mar 2021
    Primary Completion
    Apr 2021
    Completion
    Apr 2021
    NCT04784000
  • Phase 1
    Completed

    Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)

    AT-527 550 mg + cyclosporine, AT-527 550 mg + cyclosporine

    Healthy Volunteer Study

    Enrollment
    24
    Start
    Apr 2021
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT04849299
  • Phase 1
    Completed

    Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)

    AT-527 550 mg + midazolam, AT-527 550 mg + midazolam

    Healthy Volunteer Study

    Enrollment
    24
    Start
    Apr 2021
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT04865445
  • Phase 1
    Completed

    Bronchopulmonary PK of AT-527 (R07496998)

    AT-527

    Healthy Volunteer Study

    Enrollment
    24
    Start
    Apr 2021
    Primary Completion
    Aug 2021
    Completion
    Aug 2021
    NCT04877769
  • Phase 1
    Completed

    Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)

    AT-527 (R07496998)

    Healthy Volunteer Study

    Enrollment
    6
    Start
    Jul 2021
    Primary Completion
    Aug 2021
    Completion
    Aug 2021
    NCT05004415
  • Phase 1
    Completed

    Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)

    AT-527 + digoxin, AT-527 + digoxin

    Healthy Volunteers Study

    Enrollment
    29
    Start
    Nov 2021
    Primary Completion
    Dec 2021
    Completion
    Dec 2021
    NCT05137626
  • Phase 1
    Completed

    Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)

    Drug: AT-527 + rosuvastatin, AT-527 + rosuvastatin

    Healthy Volunteer Study

    Enrollment
    29
    Start
    Nov 2021
    Primary Completion
    Dec 2021
    Completion
    Dec 2021
    NCT05154123
  • Phase 1
    Completed

    Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

    AT-527 fasted, AT-527 fed

    Healthy Volunteer Study

    Enrollment
    136
    Start
    Feb 2022
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT05256732
  • Phase 1
    Terminated

    Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

    AT-752, Placebo Comparator

    Dengue

    Enrollment
    5
    Start
    Apr 2022
    Primary Completion
    Mar 2023
    Completion
    Mar 2023
    NCT05366439
  • Phase 1
    Completed

    Study of AT-527 in Subjects With Normal and Impaired Renal Function

    AT-527, AT-527

    Healthy Volunteer, Renal Impairment

    Enrollment
    36
    Start
    Oct 2022
    Primary Completion
    Jun 2024
    Completion
    Jun 2024
    NCT05618314
  • Phase 1
    Completed

    Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

    Bemnifosbuvir (BEM)

    Healthy Volunteer, Hepatic Impairment

    Enrollment
    39
    Start
    Jan 2023
    Primary Completion
    Apr 2024
    Completion
    Apr 2024
    NCT05724693
  • Phase 1
    Completed

    Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir

    Cohort 1 BEM + Ruzasvir, Cohort 2 Ruzasvir + BEM

    Healthy Volunteer Study

    Enrollment
    32
    Start
    Jan 2023
    Primary Completion
    Mar 2023
    Completion
    Mar 2023
    NCT05731843
  • Phase 1
    Completed

    Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

    Bemnifosbuvir (BEM), Placebo

    Healthy Volunteer Study

    Enrollment
    35
    Start
    Apr 2023
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT05905484
  • Phase 1
    Completed

    The Study of Bemnifosbuvir in Healthy Japanese Subjects

    Bemnifosbuvir (BEM)

    Healthy Volunteer Study

    Enrollment
    14
    Start
    Apr 2023
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT05905497

1-25 of 33

Search ClinicalTrials.gov for “Atea Pharmaceuticals”